Recent Updates
Recently added Catalysts
FATE Negative Sentiment Score: 35/100

FATE IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE

Key Takeaway: Rosen Law Firm is urging investors of Fate Therapeutics, Inc. (NASDAQ: FATE) to secure legal counsel before March 22, 2023, in light of a pending securities class action lawsuit. The suit alleges that the company made misleading statements regarding its collaboration with Janssen Biotech, potentially overstating the sustainability and future revenue reliability of their partnership. Affected investors are encouraged to join the class action to seek compensation without upfront costs. The Rosen Law Firm emphasizes the importance of selecting qualified legal representation, given their established track record in securities litigation.

Market Sentiment Analysis

CONCERNS & RISKS

  • Fate Therapeutics is facing a securities class action lawsuit due to misleading statements.
  • The lawsuit suggests that the company's collaboration with Janssen was overstated, affecting its reliability as a revenue source.
  • Investors may have suffered damages once the truth about the collaboration's sustainability was revealed.

Full Press Release Details

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2023.
SO WHAT: If you purchased Fate securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Fate class action, go to https://rosenlegal.com/submit-form/?case_id=11392 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) the global collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for cell-based cancer immunotherapies, (the “Janssen Collaboration Agreement”), was less sustainable than Fate had represented to investors; (2) accordingly, certain of the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (3) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the truth emerged, the lawsuit claims that investors suffered damages.
To join the Fate class action, go to https://rosenlegal.com/submit-form/?case_id=11392 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
Toll Free: (866) 767-3653

Tags

Frequently Asked Questions

What is the class period for Fate Therapeutics' securities?

The class period is from April 2, 2020, to January 5, 2023.

How can I join the Fate class action lawsuit?

You can join by visiting https://rosenlegal.com/submit-form/?case_id=11392.

What does being a lead plaintiff entail?

A lead plaintiff represents other class members and directs the litigation.

What allegations are made against Fate Therapeutics?

The allegations include misleading statements about collaboration agreements impacting revenue.

What fees apply to joining the Fate class action?

Participants may receive compensation without any upfront fees through a contingency arrangement.

Last updated: Mar 21, 2023